Prothena to Present Preclinical Data for PRX003 at 2016 AAAAI Annual Meeting
29 févr. 2016 16h05 HE
|
Prothena Corporation plc
DUBLIN, Ireland, Feb. 29, 2016 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq:PRTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization...
Prothena Announces Appointment of Chief Commercial Officer
24 févr. 2016 16h21 HE
|
Prothena Corporation plc
DUBLIN, Ireland, Feb. 24, 2016 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization...
Prothena Reports Fourth Quarter and Full Year 2015 Financial Results; Provides Financial Guidance and R&D Update
18 févr. 2016 16h05 HE
|
Prothena Corporation plc
Net cash used in operating and investing activities was $20.7 million in the fourth quarter and $63.8 million for the full year of 2015; net proceeds of $128.6 million raised through January 2016...
Data From Prothena’s Ongoing Phase 1/2 Clinical Trial of NEOD001 in AL Amyloidosis Published in the Journal of Clinical Oncology
09 févr. 2016 08h10 HE
|
Prothena Corporation plc
DUBLIN, Feb. 09, 2016 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel...
Prothena to Report Fourth Quarter and Full Year 2015 Financial Results and Host Webcast Conference Call on February 18
04 févr. 2016 16h05 HE
|
Prothena Corporation plc
DUBLIN, Ireland, Feb. 04, 2016 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq:PRTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization...
Prothena to Participate in BIO CEO & Investor and Leerink Partners Healthcare Conferences
01 févr. 2016 16h05 HE
|
Prothena Corporation plc
DUBLIN, Ireland, Feb. 01, 2016 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization...
Prothena Announces Pricing of Public Offering of 2,250,000 Ordinary Shares
07 janv. 2016 08h00 HE
|
Prothena Corporation plc
DUBLIN, Ireland, Jan. 07, 2016 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization...
Prothena Announces Proposed Offering of Ordinary Shares
05 janv. 2016 16h01 HE
|
Prothena Corporation plc
DUBLIN, Ireland, Jan. 05, 2016 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization...
Prothena to Participate in Oppenheimer and RBC Capital Markets Healthcare Investor Conferences
01 déc. 2015 16h05 HE
|
Prothena Corporation plc
DUBLIN, Ireland., Dec. 01, 2015 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization...
Prothena to Present New Preclinical Data for NEOD001 at 57th Annual American Society of Hematology Meeting
05 nov. 2015 09h20 HE
|
Prothena Corporation plc
DUBLIN, Ireland, Nov. 05, 2015 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq:PRTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization...